Eric Dippel is a Cardiology physician affiliated with Midwest Cardiovascular Research Foundation. OpenAlex indexes 61 publications with 1,705 citations (h-index 21); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention
Sponsor: Midwest Cardiovascular Research Foundation
- Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis
Sponsor: Spectranetics Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
8 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
67.3%Phosphodiesterase 3 Inhibitor27.9%Cilostazol100%Part D≥12 patientsP2Y12 inhibitor21.8%Clopidogrel100%Part D≥20 patients+ 1 more class in this area
Nervous system
24.8%N-methyl-D-aspartate Receptor Antagonist8.5%Memantine Hcl100%Part D<11 patientsAtypical Antipsychotic8.5%Quetiapine Fumarate100%Part D<11 patients+ 1 more class in this area
Cardiovascular
7.9%Nitrate7.9%Isosorbide Mononitrate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The CLTI Paradigm Shift: Implications for Clinical Trial Design and Endpoints in Endovascular Management of Infrapopliteal Disease
Journal of Endovascular Therapy
2025 - A universal drug delivery catheter for the treatment of infrapopliteal arterial disease using liquid therapy
Catheterization and Cardiovascular Interventions
2020 - Multidisciplinary approach to the diagnosis and management of patients with peripheral arterial disease
Clinical Interventions in Aging
2015 - Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis
JACC: Cardiovascular Interventions
2014 - TCT-531 EXCITE ISR: A Prospective, Randomized Controlled Trial of Excimer Laser Atherectomy vs Balloon Angioplasty for the Treatment of Femoropopliteal In-Stent Restenosis
Journal of the American College of Cardiology
2014
Similar KOLs
Other experts from the same institution or the same specialty.
Nicolas Shammas, MD
Midwest Cardiovascular Research Foundation
Peter Sharis, MD
Midwest Cardiovascular Research Foundation
Edmund Coyne, MD
Midwest Cardiovascular Research Foundation
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”